These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 28532773)

  • 1. Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
    Mugnai G; de Asmundis C; Iacopino S; Stroker E; Longobardi M; De Regibus V; Coutino-Moreno HE; Takarada K; Choudhury R; Abugattas de Torres JP; Storti C; Brugada P; Chierchia GB
    Am J Cardiol; 2017 Jul; 120(2):223-229. PubMed ID: 28532773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
    Tscholl V; Lsharaf AK; Lin T; Bellmann B; Nagel P; Lenz K; Landmesser U; Roser M; Rillig A
    Clin Cardiol; 2017 Nov; 40(11):1095-1099. PubMed ID: 28846806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.
    Koektuerk B; Turan CH; Yorgun H; Keskin K; Schoett M; Dahmen A; Gorr E; Yang A; Hoppe C; Horlitz M; Turan RG
    Cardiovasc Ther; 2016 Jun; 34(3):144-51. PubMed ID: 26880220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
    Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
    Liu X; Xu ZX; Yu P; Yuan P; Zhu WG
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):569-578. PubMed ID: 32297024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
    Schäfer A; Flierl U; Berliner D; Bauersachs J
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):555-568. PubMed ID: 32350792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
    Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
    Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 18. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion.
    Gawałko M; Kapłon-Cieślicka A; Budnik M; Babiarz A; Bodys A; Uliński R; Żochowski M; Peller M; Scisło P; Kochanowski J; Filipiak KJ; Opolski G
    Pol Arch Intern Med; 2017 Dec; 127(12):823-831. PubMed ID: 28972957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.